Which statement is true about short-term IOP lowering with brimonidine/apraclonidine?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

Which statement is true about short-term IOP lowering with brimonidine/apraclonidine?

Explanation:
Short-term lowering of IOP with alpha-2 agonists depends on how strongly and how long the drug continues to affect aqueous humor production. Brimonidine generally produces a larger reduction in IOP and maintains its effect well with brief use, whereas apraclonidine, although it may produce a quicker initial drop, is more prone to tachyphylaxis and irritation with repeated dosing, which blunts its short-term effectiveness. So, in the first day or so of use, brimonidine tends to give a greater and faster IOP decrease than apraclonidine.

Short-term lowering of IOP with alpha-2 agonists depends on how strongly and how long the drug continues to affect aqueous humor production. Brimonidine generally produces a larger reduction in IOP and maintains its effect well with brief use, whereas apraclonidine, although it may produce a quicker initial drop, is more prone to tachyphylaxis and irritation with repeated dosing, which blunts its short-term effectiveness. So, in the first day or so of use, brimonidine tends to give a greater and faster IOP decrease than apraclonidine.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy